HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Maintenance sorafenib is superior to prophylactic donor lymphocyte infusion at improving the prognosis of acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication after allogeneic hematopoietic stem cell transplantation.

AuthorsJimin Shi, Liqin Cao, Yi Luo, Yanmin Zhao, Yamin Tan, Jian Yu, Xiaoyu Lai, Yuanyuan Zhu, Yongxian Hu, Jingsong He, Jie Sun, Weiyan Zheng, Guoqing Wei, He Huang
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 56 Issue 1 Pg. 293-296 (01 2021) ISSN: 1476-5365 [Electronic] England
PMID32753705 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Sorafenib
  • fms-Like Tyrosine Kinase 3
Topics
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Leukemia, Myeloid, Acute (therapy)
  • Lymphocytes
  • Mutation
  • Prognosis
  • Sorafenib (therapeutic use)
  • fms-Like Tyrosine Kinase 3

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: